Materials And Products Related To Genetic Engineering Or Hybrid Or Fused Cell Technology, E.g., Hybridoma, Monoclonal Products, Etc. Patents (Class 530/808)
-
Patent number: 5077391Abstract: Immunoglobulin M is purified by absorption upon an insoluble matrix material having chemically bound thereon the protein C1q. The matrix is washed and purified immunoglobulin M is then released from the matrix.Type: GrantFiled: December 1, 1989Date of Patent: December 31, 1991Inventors: Robert L. Raison, Simon B. Easterbrook-Smith, Andrew G. Nethery
-
Patent number: 5073627Abstract: A fusion protein is disclosed which comprises GM-CSF and IL-3. Such fusion proteins more biologically active than GM-CSF or IL-3 alone or GM-CSF and IL-3 combined.Type: GrantFiled: August 14, 1990Date of Patent: December 17, 1991Assignee: Immunex CorporationInventors: Benson M. Curtis, Linda S. Park, David J. Cosman
-
Patent number: 5071744Abstract: Pancreatic .alpha.-amylase is determined in body fluid in the presence of salivary .alpha.-amylase by combining the body fluid with a monoclonal antibody that inhibits salivary .alpha.-amylase by 95% or more and inhibits pancreatic .alpha.-amylase by 50% or less, and then detecting pancreatic .alpha.-amylase with a system for the detection of .alpha.-amylase. The monoclonal antibody may be in immobilized form. The monoclonal antibody is preferably produced by immunizing a Balb/c mouse or an AJ mouse with a specific immunogen for a specific number of times, fusing .beta.-lymphocytes obtained from the mouse with a myeloma cell line to form an antibody producing hybridoma cell line, cloning and screening the hybridoma cell line for the desired monoclonal antibody, and isolating the monoclonal antibody. The immunogen contains modified or unmodified salivary .alpha.-amylase, aluminum hydroxide and Bortadella pertussis.Type: GrantFiled: October 9, 1990Date of Patent: December 10, 1991Assignee: Boehringer Mannheim GmbHInventors: Kurt Naujoks, Karl Wulff, Martin Gerber
-
Patent number: 5071962Abstract: The present invention relates to novel polypeptides comprising a unique "chlamydial-specific" primary structural conformation and one or more of the biological properties of eukaryotic or prokaryotic stress-response proteins which are characterized by being the expressed products of an endogenous or exogenous DNA sequence in a eukaryotic or prokaryotic host cell. Sequences coding for part or all of the amino acid residues of the chlamydial HypA or HypB protein or for analogs thereof may be incorporated into autonomously replicating vectors employed to transform or transfect suitable procaryotic or eukaryotic host cells such as bacteria or vertebrate cells in culture. The HypB protein is a member of the family of stress response proteins referred to as HSP60. Products of expression of the DNA sequences display the identical physical, immunological, and histological properties as the chlamydial proteins isolated from natural, non-recombinant, organisms.Type: GrantFiled: May 31, 1990Date of Patent: December 10, 1991Assignee: The United State of America as represented by the Department of Health and Human ServicesInventors: Richard P. Morrison, Harlan D. Caldwell
-
Patent number: 5059521Abstract: The invention relates to monoclonal antibodies against prosomal proteins of a prosome, said prosome having a sedimentation coefficient of approximately 19S, and to a method for detecting cancer using monoclonal antibodies specifically directed against said prosomal proteins. The invention also relates to diagnostic reagents for use in such a detection method.Type: GrantFiled: January 17, 1989Date of Patent: October 22, 1991Assignee: Pro-SomaInventors: Klaus Scherrer, Maria-Fatima Grossi de Sa
-
Patent number: 5057598Abstract: Novel monoclonal antibodies are disclosed, the production of which is specified by particular genes contained, conveniently, in biologically pure cultures of self-reproducing carrier cells, such as, but not limited to, ATCC HB 8297 and ATCC HB 8298, such antibodies being reactive with at least part of endotoxin core of Gram-negative bacteria. Processes of prepaU.S. GOVERNMENT RIGHTSThe invention described herein may be manufactured, used and licensed by or for the U.S. Government for governmental purposes only without the payment to the inventors of any royalties thereon.Type: GrantFiled: February 1, 1989Date of Patent: October 15, 1991Assignee: Centocor, Inc.Inventors: Matthew Pollack, Kenneth W. Hunter
-
Patent number: 5053224Abstract: A method of inducing an immunological response to solid tumors is provided wherein anti-idiotype antibodies presenting an internal image of a tumor or antigen are administered to a patient. Monoclonal anti-idiotype antibodies and immortal B lymphocytes that produce them are also provided.Type: GrantFiled: August 26, 1987Date of Patent: October 1, 1991Inventors: Hilary Koprowski, Dorothee Herlyn, Elaine C. DeFreitas
-
Patent number: 5053327Abstract: Hybrid cell lines (hybridomas) which produce and secrete high affinity monoclonal antibodies specific for Bowman-Birk inhibitor (BBI) are described. High affinity antibodies to BBI are described that have one or more of the following additional characteristics: (1) they are specific to the active form of BBI, that is, they react and bind with undenatured BBI, but do not bind with BBI which has been denatured by heat or disulfide exchange; (2) they do not react and bind with KTI; (3) they distinguish classical BBI from other BBI's including lima bean protease inhibitor; and (4) they bind BBI-protease complex, e.g., BBI-chymotrypsin. Immunoassay methods using the monoclonal antibodies to analyze BBI specifically in plant, animal or human tissue or fluid or foodstuffs and techniques for immunoaffinity binding of BBI are described.Type: GrantFiled: September 20, 1988Date of Patent: October 1, 1991Assignee: The United States of America as represented by the Secretary of AgricultureInventors: David L. Brandon, Anne H. Bates, Mendel Friedman
-
Patent number: 5043288Abstract: Molecular binding partners such as antibodies and haptens are immobilized to support materials that have the property of contact activation of blood protein coagulation. A binding partner is attached to a surface-active protein carrier and the resulting conjugate non-covalently adsorbs onto the surface of the support. The method provides for diagnostic assays of greater sensitivity and convenience.Type: GrantFiled: June 20, 1988Date of Patent: August 27, 1991Inventor: Marvin A. Motsenbocker
-
Patent number: 5043156Abstract: A method of treating an infectious disease by administering both a granulocyte colony stimulating factor (G-CSF) and an antimicrobial agent is disclosed. Also disclosed is a kit for treatment of an infectious disease that comprises an antimicrobial agent and a pharmaceutical drug having G-CSF as the effective ingredient. The resistance of a patient against infection is enhanced by administration of G-CSF, and this augments the therapeutic effect of an antimicrobial agent to be subsequently administered. By the synergistic effect of G-CSF and the antimicrobial agent, the infectious diseases can be treated in a very effective manner.Type: GrantFiled: November 23, 1988Date of Patent: August 27, 1991Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Masahiko Matsumoto, Shuzo Matsubara
-
Patent number: 5039611Abstract: There is provided four distinct hybrid cell lines bearing numbers M75, M300, M344 and 19A211, each producing a different monoclonal antibody of class lgG1, each antibody when used alone or in combination with one or more of the other three antibodies being capable of selective binding with one or more distinct antigens produced by superficial papillary bladder tumors of the human urinary bladder. There is also provided a method for producing such cell lines as well as a method and a test kit for the detection of distinct antigens produced by superficial papillary bladder turmors of the human urinary bladder. Provision is also made for use in flow cytometry (single or multiple laer) and in biosensors for detect of these antigens.Type: GrantFiled: September 28, 1987Date of Patent: August 13, 1991Assignee: Universite LavalInventor: Yves Fradet
-
Patent number: 5034316Abstract: Human monoclonal IgG RF is provided in stable supply from immortalized cells. The IgG RF can be used for diagnosis and study of rheumatoid arthritis. In addition, anti-idiotype antibodies can be provided for use in diagnosis and therapy.The cell line hRF-1 was deposited at the A.T.C.C. on January 16, 1991 and given accession No. ATCC 10645.Type: GrantFiled: March 30, 1987Date of Patent: July 23, 1991Assignee: The Regents of the University of CaliforniaInventors: Richard H. Weisbart, Romaine E. Saxton
-
Patent number: 5032521Abstract: Hybridomas are provided which secrete an IgG1 or IgG2 monoclonal antibody which binds to an epitope on an antigen, which occurs in the plasma membrane of MCF-7 cells and has a molecular weight of 22 kD. The epitope of the antibodies is exposed on the extracellular side of the plasma membrane of the MCF-7 cells. The monoclonal antibodies, which react generally with human mammary carcinoma cells, but with few non-mammary cancer cells, are useful diagnostically and therapeutically.Type: GrantFiled: March 23, 1987Date of Patent: July 16, 1991Assignee: The Salk Institute for Biological StudiesInventors: Christine A. White, Renato Dulbecco, William R. Allen
-
Patent number: 5030621Abstract: A human anti-cancer vaccine is prepared by culturing human cancer cells, such as human melanoma cells, human lung cancer cells, human colon cancer cells, human breast cancer cells, and other human cancer cells in a serum-free medium. The cells are selected on the basis of expressing different patterns of cell surface tumor antigens and are adapted to and are grown in a serum-free medium. During culturing antigens of the cancer cells are shed into the culture medium. The culture medium, containing the shed cancer cell antigens, is then concentrated, such as by vacuum ultrafiltration. In some instances the vaccine is then treated with a non-ionic surfactant or detergent, such as Nonidet P-40 (NP-40), to break up aggregates and treated with a presevative, such as sodium azide, and then subjected to ultracentrifugation.Type: GrantFiled: February 22, 1990Date of Patent: July 9, 1991Inventor: Jean-Claude Bystryn
-
Patent number: 5021553Abstract: A monoclonal antibody against human cancer, characterized in that the monoclonal antibody is produced by a hybridoma cell line obtained from the fusion of B-lymphocyte immunized with cells of human cancer origin and tumor cells, and reactive with cancer cells from more than one organ but substantially not reactive with normal cells, and a process for production thereof; and a hybridoma cell line used to produce the above-mentioned monoclonal antibody, and a process for production thereof.Type: GrantFiled: July 10, 1989Date of Patent: June 4, 1991Assignee: Wakunaga Seiyaka Kabushiki KaishaInventors: Eiichi Tahara, Atsushi Ochiai, Hiroshi Yokozaki, Toyoharu Hozumi, Eikai Kyo
-
Patent number: 5019497Abstract: Methods and compositions are provided for detecting antigens having a specific epitope associated with squamous lung carcinoma. The antigen may be found at lesion sites or in the blood as indicative of the squamous lung carcinoma.Specific antibodies may be used for the detection of the antigen and in therapy.The mouse hybridoma 43-9F producing IgM monoclonal antibody 43-9F and SLC cell RH-SLC-L11 were deposited at The PHLS Centre for Applied Microbiology and Research, Porton Down, Salisbury, U.K. on Jan. 31, 1985 and given Accession Nos. 85013101 and 85061403, respectively.Type: GrantFiled: July 5, 1988Date of Patent: May 28, 1991Inventor: Lennart Olsson
-
Patent number: 5008198Abstract: The invention comprises antigenic glycoproteins substantially similar to antigenic glycoproteins present on the surface of the merozoite form of Plasmodium falciparum, including glycoproteins of molecular weights of about 56,000 present in the Geneva and FVO isolates and about 50,000 that is present in the Honduras I/CDC, Indochina 1, Kenya and Tanzania I isolates. The invention also comprises monoclonal antibodies 4-8-5D (HB 8938) which bind to the 56,000 glycoprotein of the invention, a hybridoma cell line that is capable of producing these monoclonal antibodies, and vaccines and vaccine compositions comprising these glycoproteins or epitopes substantially similar to or cross reactive with these glycoproteins or genes or gene fragments encoding such epitopes.Type: GrantFiled: May 30, 1989Date of Patent: April 16, 1991Assignee: Scripps Clinic and Research FoundationInventors: Robert T. Reese, Harold A. Stanley
-
Patent number: 5004694Abstract: Novel monoclonal antibodies specific to Trichomonas vaginalis, having complement--fixing ability and lysing Trichomonas vaginalis in the presence of complement are disclosed and may be used in therapy and diagnosis of trichomoniasis. Hybridomas producing and compositions comprising these antibodies are also disclosed.Type: GrantFiled: September 4, 1987Date of Patent: April 2, 1991Assignee: Interpharm Laboratories Ltd.Inventors: Neomi Moay, Enrica Draghi
-
Patent number: 5003046Abstract: The invention concerns a novel lymphocyte hybridoma and an antibody which may be generated from the hybridoma. The hybridoma and antibody have the internal designation LICR-LON-Fib 75. The origin, method of preparation and uses are discussed. The antibody has particular application in the diagnosis and treatment of cancer of the breast. A particular therapeutic treatment comprises harvesting a sample of bone marrow from a patient, subjecting the patient to treatment adapted to kill cancerous material including that within the bone marrow (possibly including the normal differentiated haemopoietic cells of the marrow), subjecting some or all of the sample to cytotoxic treatment with the antibody (or a toxin conjugate thereof) adapted to kill cancerous cell lines while leaving viable colony-forming units of bone marrow, and reintroducing the treated sample material to the blood stream of the patient.Type: GrantFiled: December 23, 1987Date of Patent: March 26, 1991Assignee: Ludwig Institute for Cancer ResearchInventors: Alexander M. Neville, Christopher S. Foster, Paul A. W. Edwards, Robert A. J. McIlhinney
-
Patent number: 5001225Abstract: A continuous hybridoma cell line, designated 7H8, which secretes a monoclonal antibody (MAb 7H8) of the IgM class and which binds to a protein present in species of the genus Plasmodium. MAb 7H8 also recognizes an antigen (antigen Pf93) unique to P. falciparum. Methods of isolating the substantially pure antigen using the antibody of the present invention are disclosed. MAb 7H8 is well suited for use in immunometric assays. Preferred is a two-sited assay developed with MAb 7H8. Anti-idiotypic and anti anti-idiotypic antibodies to MAb 7H8 are disclosed. The antibodies and antigens of the present invention are useful for immunodiagnostic and immunotherapeutic treatment of malarial diseases of man and animals.Type: GrantFiled: December 8, 1986Date of Patent: March 19, 1991Assignee: Georgetown UniversityInventor: Diane W. Taylor
-
Patent number: 4997764Abstract: Disclosed herein is a method for transforming human B-cells by infecting them with Epstein Barr virus and transfecting the Epstein Barr virus infected cells with an activated human c-myc gene. The transformed cells are useful for producing human monoclonal antibodies.Type: GrantFiled: April 23, 1987Date of Patent: March 5, 1991Assignee: New York UniversityInventor: Ricardo Dalla Favera
-
Patent number: 4997762Abstract: Hybridoma cell lines and transformed B-cell lines are derived from B-cells of cancer patients actively immunized with autologous tumor antigens and used to produce monoclonal antibodies having specificity for tumor-associated antigens. The monoclonal antibodies can be used in both diagnostic procedures and therapy for human cancers.Type: GrantFiled: April 15, 1987Date of Patent: March 5, 1991Assignee: Akzo N.V.Inventors: Michael Hanna, Jr., Martin V. Haspel, Herbert C. Hoover, Jr.
-
Patent number: 4996297Abstract: The invention relates to antigenic preparations useful for inducing the production of antibodies in an individual which will bind to epitopes on zona pellucida. Also disclosed are immunogenic compositions and methods for immunizing an individual to enable the production of antibodies to zona pellucida antigens. Also disclosed are the use of these recombinant molecules and monoclonal antibodies thereto for immunocontraception or sterilization.Type: GrantFiled: October 7, 1987Date of Patent: February 26, 1991Assignee: Zonagen, Inc.Inventor: Bonita S. Dunbar
-
Patent number: 4990326Abstract: Use of labeled monoclonal antibody 50 H.19 to detect the location and concentration of blood platelets in a host is disclosed. MAb 50 H.19 labeled with a label which can be detected from without the host (e.g. a radiolabel or NMR-label) is intravenously injected to immunoreact with platelets in vivo or is first immunoreacted in vitro with platelets, which are then intravenously injected into the host. By means of the labeled MAb 50 H.19 bound platelets it is possible to detect and locate thrombi, emboli, atherosclerotic obstructions, bacterial endocarditis and to do spleen imaging. In another embodiment of the invention, the MAb 50 H.19 is bound to an enzymatic thrombolytic agent and injected intravenously to permit the therapeutic application of the agent directly to thrombi.Type: GrantFiled: March 15, 1988Date of Patent: February 5, 1991Assignee: Summa Medical CorporationInventors: Antoine A. Noujaim, Bryan M. Longenecker
-
Patent number: 4990454Abstract: A monoclonal antibody specifically reactive to a human adenocarcinoma cell, which is obtainable by cultivating a fused cell obtained by fusing a mammalian animal cell, immunized with a human adenocarcinoma cell, with a myeloma cell.Type: GrantFiled: January 12, 1990Date of Patent: February 5, 1991Assignee: Nihon Medi-Physics Co., Ltd.Inventors: Akira Yachi, Kohzoh Imai, Takao Endo, Yuji Hinoda, Takafumi Yamashita, Hideo Fujita
-
Patent number: 4977086Abstract: Murine monoclonal antibodies specific to unique antigenic determinants on mammalian terminal deoxynucleotidyl transferases (TdT). The monoclonal antibodies specifically bind to TdT in a wide variety of mammalian cells including human, mouse, rat, rabbit and bovine origin. The monoclonal antibodies are secreted by hybridoma cell lines derived from fusion of murine plasmacytoma cells with splenocytes from mice immunized with TdT from bovine thymus cells. The monoclonal antibodies can detect small numbers of TdT-positive cells from monitoring of TdT-positive leukemias and lymphomas in multple species, including human.Type: GrantFiled: June 12, 1989Date of Patent: December 11, 1990Assignee: The Board of Regents of the University of Texas SystemInventor: R. Graham Smith
-
Patent number: 4971792Abstract: The present invention is directed to in vitro and in vivo immunodiagnosis and immunotherapy using monoclonal antibodies reactive with difucosyl blood group antigens Y-6 and B-7-2.Type: GrantFiled: March 27, 1987Date of Patent: November 20, 1990Assignee: The Wistar InstituteInventors: Zenon Steplewski, Hilary Koprowski, Magdelena Thurin
-
Patent number: 4970070Abstract: Immortalized cell lines have been produced that secrete human monoclonal antibodies capable of binding to bacterial species which are a major cause of neonatal sepsis and meningitis. These antibodies have been found to be protective against lethal challenges of these bacteria, which include group B streptococcus, E. coli, K1, and Neisseria meningitidis group B. Pharmaceutical compositions containing these antibodies, which can be in combination with other monoclonal anitbodies, blood plasma fractions and antimicrobial agents, and the prophylactic and therapeutic use of such compositions in the management of infections, are included.Type: GrantFiled: May 2, 1988Date of Patent: November 13, 1990Assignee: Genetic Systems CorporationInventor: Howard V. Raff
-
Patent number: 4966837Abstract: Recombinant DNA transfer vectors containing DNA inserts which are complementary to either the human LDL receptor gene, or its mRNA transcript, are disclosed. Also disclosed are methods which utilize these genetic probes for diagnosing Familial Hypercholesterolemia (FH) in a suspected individual. A case study of numerous such individual are disclosed wherein the genetic deletion mutation is detailed with great precision through the practice of this invention.Type: GrantFiled: October 30, 1986Date of Patent: October 30, 1990Assignee: Board of Regents, The University of Texas SystemInventors: Michael S. Brown, Joseph L. Goldstein, David W. Russell
-
Patent number: 4963355Abstract: Process for producing an antibody catalyst for a chemical reaction. Chemical reactions in which the antibody catalyst can be used are also disclosed.Type: GrantFiled: June 19, 1987Date of Patent: October 16, 1990Assignee: Igen, Inc.Inventors: Peter S. Kim, Neville R. Kallenbach
-
Patent number: 4962048Abstract: Novel hybridoma cell lines producing monoclonal antibodies which react specifically with human pancreatic cancer cells are described. Methods for producing antigenic preparations to generate the hybridoma cell lines and for selecting, purifying and characterizing the monoclonal antibodies reactive with human cells, including pancreatic cancer cells, are disclosed.Type: GrantFiled: April 3, 1989Date of Patent: October 9, 1990Assignee: Scripps Clinic & Research FoundationInventors: Shama Kajiji, Vito Quaranta
-
Patent number: 4962188Abstract: Conjugates comprising recombinant ricin toxin A chain and a binding moiety which may be an antigen binding portion selected from the group consisting of Fab, Fab' and F(ab').sub.2 fragments of monoclonal or polyclonal antibodies, hormones, lectins or other compounds that are recognized by cell receptors, are described and claimed.Type: GrantFiled: September 30, 1986Date of Patent: October 9, 1990Assignee: Cetus CorporationInventor: Arthur E. Frankel
-
Patent number: 4959457Abstract: Antibody is provided which is capable of neutralizing the in vitro anti-neoplastic cellular activity of lymphotoxin. This antibody, which preferably is produced of monoclonal fusions, can be used in assays for lymphotoxin or for immunoaffinity purification of lymphotoxin.Type: GrantFiled: May 31, 1984Date of Patent: September 25, 1990Assignee: Genentech, Inc.Inventor: Timothy S. Bringman
-
Patent number: 4958009Abstract: Immunotoxins comprising a cytotoxic moiety and monoclonal antibodies which bind to human ovarian cancer tissue having at least one of the following capabilities are claimed: cytotoxic ID.sub.50 of 10 nM or less against human ovarian cancer cells, retardation of human ovarian cancer tumor growth in mammals or extension of survival of a mammal carrying a human ovarian cancer tumor. Antigens to which the monoclonal antibody of the immunotoxin bind are identified and characterize the immunotoxins. Methods of killing human ovarian cancer cells, retarding the growth of human ovarian cancer tumors in mammals or extending the survival of mammals carrying human ovarian cancer tumors are claimed.Type: GrantFiled: July 6, 1987Date of Patent: September 18, 1990Assignee: Cetus CorporationInventors: Michael J. Bjorn, David J. FitzGerald, Arthur E. Frankel, Walter J. Laird, Ira H. Pastan, David B. Ring, Mark C. Willingham, Jeffrey L. Windelhake
-
Patent number: 4956453Abstract: Immunotoxins comprising a cytotoxic moiety and an antigen binding portion selected from the group consisting of Fab, Fab' and F(ab').sub.2 fragments of a monoclonal antibody, which binds to human ovarian cancer tissue, having one of the following capabilities are claimed: cytotoxic ID.sub.50 of about 10 nM or less against human ovarian cancer cells, retardation of human ovarian cancer tumor growth in mammals, or extension of survival of a mammal carrying a human ovarian cancer tumor. Antigens or epitopes to which the monoclonal antibodies bind are identified and characterize the immunotoxins. In a preferred embodiment an immunotoxin comprising at least an antigen binding portion of a monoclonal antibody, which binds to human transferrin receptor, but does not block binding of transferrin to the receptor, is described and claimed. Immunotoxin comprising the F(ab').sub.2 region of the antitransferrin monoclonal antibody are also claimed.Type: GrantFiled: July 6, 1987Date of Patent: September 11, 1990Assignee: Cetus CorporationInventors: Michael J. Bjorn, Arthur E. Frankel, Walter J. Laird, David B. Ring, Jeffrey L. Winkelhake
-
Patent number: 4956454Abstract: Platinum co-ordination compounds comprising at least one amine ligand and a functional group remotely bonded to the amine ligand, which functional group may be linkable to a monoclonal antibody to provide a moiety which stabilizes the antibody against in vivo hydrolysis.Type: GrantFiled: April 21, 1988Date of Patent: September 11, 1990Assignee: Johnson Matthey PLCInventors: James G. Heffernan, Paul C. Hydes, Donald H. Picker
-
Patent number: 4952676Abstract: A platinum co-ordination compound linkable to a monoclonal antibody by a functional group which forms part of a moiety which stabilizes the antibody against in vivo hydrolysis. Also the use of such compounds in the treatment of cancer.Type: GrantFiled: July 20, 1988Date of Patent: August 28, 1990Assignee: Johnson Matthey PLCInventors: James G. Heffernan, Michael J. Cleare, Donald H. Picker
-
Patent number: 4950741Abstract: A substantially pure rheumatoid arthritis specific protein (RASP) and an antibody against the rheumatoid arthritis specific protein (anti-RASP antibody) are disclosed. The RASP is found specifically in the serum or plasma of a patient suffering from rheumatoid arthritis, and may be detected using an anti-RASP antibody easily and effectively. Therefore, the anti-RASP antibody of the present invention is useful for the diagnosis of rheumatoid arthritis by the criterion of the presence of RASP.Type: GrantFiled: February 16, 1988Date of Patent: August 21, 1990Assignees: Asahi Medical Co., Ltd., Medecs Co., Ltd.Inventors: Naoki Yamanaka, Makoto Yoshida
-
Patent number: 4945041Abstract: Monoclonal antibodies specific for Mycoplasma pneumoniae determinants and their use in the diagnosis of mycoplasma pneumoniae and purification of a protein determinant of M. pneumoniae.Type: GrantFiled: January 9, 1987Date of Patent: July 31, 1990Assignee: Board of RegentsInventor: Joel B. Baseman
-
Patent number: 4939082Abstract: In body fluids containing saliva alpha amylase and pancreatic alpha amylase, pancreatic alpha amylase is determined with a monoclonal antibody which specifically binds but does not inhibit saliva alpha amylase and which has a cross-reactivity of 5% or less toward pancreatic alpha amylase. The monoclonal antibody binds salvia alpha amylase to form a complex which is separated to permit determining pancreatic alpha amylase with an amylase detection system. The complex may be separated by precipitating with a precipitating agent such as an anti-antibody or protein A, or by immobilizing the monoclonal antibody on a solid carrier.Type: GrantFiled: March 21, 1989Date of Patent: July 3, 1990Assignee: Boehringer Mannheim GmbHInventors: Kurt W. Naujoks, Willie Gerhardt, Christa Hubner-Parajsz, Karl Wulff, Herbert Jungfer, Helmut Lenz, Winfried Albert, August W. Wahlefeld
-
Patent number: 4938948Abstract: Hybridomas producing monoclonal antibodies suitable for imaging and diagnosis of human breast tumors and such monoclonal antibodies are claimed. The monoclonals are characterized by breast tumor binding range, breast cancer cell line range, and selectivity.Immunoimaging agents comprising the monoclonal antibody and a detectable label, either directly or indirectly conjugated to the antibody are claimed. Methods for imaging breast tumors using the immunoimaging agents are described and claimed.Type: GrantFiled: October 11, 1985Date of Patent: July 3, 1990Assignee: Cetus CorporationInventors: David B. Ring, Arthur E. Frankel
-
Patent number: 4939240Abstract: Monoclonal antibodies to adenocarcinoma cells, and, in particular, breast carcinoma cells, are produced by a hybridoma formed by fusing mouse lymphocytes and mouse myeloma cells. The monoclonal antibodies are capable of shrinking solid tumors associated with human breast. The monoclonal antibodies identify an antigen associated with carcinomas of ductal lineage. The monoclonal antibodies, specifically, F36/22 monoclonal antibodies, can be used diagnostically and therapeutically.Type: GrantFiled: September 11, 1985Date of Patent: July 3, 1990Assignee: Health Research, Inc.Inventors: Tsann M. Chu, Lawrence D. Papsidero
-
Patent number: 4939094Abstract: The present invention provides a hybrid antigen polypeptide having both antigenicity of the ATLA encoded by gag gene and that of the ATLA encoded by env gene. The hybrid antigen can be produced in a large amount and it is applicable to serum diagnosis of patients infected with antigen polypeptides such as ATLV.Type: GrantFiled: August 15, 1986Date of Patent: July 3, 1990Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Tetsuro Kuga, Susumu Sekine, Seiga Itoh
-
Patent number: 4935496Abstract: A mouse-human chimaeric immunoglobulin heavy chain comprising (a) the amino acid sequence of a mouse immunoglobulin heavy chain variable region and (b) the amino acid sequence of a human immunoglobulin heavy chain constant region and reacting specifically with human common acute lympohocytic leukemia antigen and a chimaeric DNA fragment which encodes the amino acid sequence of the above mouse-human chimaeric immunoglobulin heavy chain.Type: GrantFiled: December 4, 1985Date of Patent: June 19, 1990Assignee: Teijin LimitedInventors: Akira Kudo, Yushi Nishimura, Yataro Ichikawa, Takeshi Watanabe
-
Patent number: 4935234Abstract: A method of reducing tissue injury in humans or other animal species using a monoclonal antibody to inhibit specific phagocyte functions. The monoclonal antibody is selected to bind to phagocytic leukocytes for the purpose of inhibiting migration to an inflammatory site in the body and to inhibit the adhesion and spreading of activated leukocytes reaching such an area and then, block release of toxic substances by these cells. The monoclonal antibody is administered in vivo prior or early in the course of an experience leading to an injurious inflammatory response such as can result from restoration of myocardial blood flow interrupted by an acute coronary thrombosis.Type: GrantFiled: March 7, 1988Date of Patent: June 19, 1990Assignee: Dana-Farber Cancer InstituteInventors: Robert F. Todd, III, Paul J. Simpson, Benedict R. Lucchesi, Stuart F. Scholossman, James D. Griffin
-
Patent number: 4927916Abstract: Peptides comprising fibrin-specific epitopic sequences are used to prepare hybridoma cell lines producing antifibrin-specific monoclonal antibodies substantially devoid of fibrinogen-cross-reactivity obtained by somatic cell fusion. The antibodies are useful for the in vivo and in vitro detection of thrombi and fibrin deposits.Type: GrantFiled: January 30, 1986Date of Patent: May 22, 1990Assignee: The General Hospital CorporationInventors: Gary R. Matsueda, Edgar Haber, Kwan Hui
-
Patent number: 4925787Abstract: A monoclonal anti-idiotypic antibody specific to a human IgG.sub.1 type monoclonal antibody possessing specificity to nicotinic acetylcholine receptor; a method for the production of the aforementioned monoclonal anti-idiotypic antibody by the steps of immunizing an animal with a human IgG.sub.1 type monoclonal antibody specific to nicotinic acetylcholine receptor, collecting antibody-producing cells from the animal, fusing the collected cells with neoplastic cells, selecting from the product of fusion a hybridoma capable of producing a monoclonal anti-idiotypic antibody specific to the human IgG.sub.1 type monoclonal antibody possessing specificity to nicotinic acetylcholine receptor, propagating the selected hybridoma thereby giving rise to said monoclonal anti-idiotypic antibody, and collecting the produced monoclonal anti-idiotypic antibody; and use of the monoclonal anti-idiotypic antibody as a reagent and as an adsorbent.Type: GrantFiled: March 30, 1988Date of Patent: May 15, 1990Assignees: Agency of Industrial Science and Technology, Ministry of International Trade and IndustryInventors: Masao Tanihara, Hideaki Yamada, Toshihide Nakashima, Yoshiaki Omura, Koichi Takakura
-
Patent number: 4925922Abstract: Novel compositions and methods are provided for the treatment of cancer employing monoclonal antibodies (MoAbs) conjugated to a toxin. According to the present invention, MoAbs defining epitopes on either a tumor associated glycoprotein antigen of about 72 kD m.w. or on carcinoembryonic antigen conjugated to a ribosomal inhibiting protein, or the like, are employed either alone or in combination as cytotoxic agents in the treatment of various cancers including, but not limited to, colorectal carcinoma, ovarian carcinoma and osteogenic sarcoma. For some of these compositions, an enhanced or potentiated efficacy is observed when the conjugates are administered along with a related, unconjugated monoclonal antibody.Hybridomas XMMCO-791 and XMMCO-228 were deposited with the A.T.C.C. on Aug. 14, 1986 and given A.T.C.C. Accession Nos. HB 9173 and HB 9174, respectively. Hybridoma XMMBR-B14 was deposited with the A.T.C.C. on Jan. 14, 1987 and given A.T.C.C. Accession No. HB 9308.Type: GrantFiled: May 8, 1989Date of Patent: May 15, 1990Assignee: Xoma CorporationInventors: Vera S. Byers, Robert W. Baldwin, Patrick J. Scannon
-
Patent number: 4921790Abstract: The present invention relates to a 40 kilodalton subunit of serous cystadinocarcinoma ovarian tumor associated antigen CA125, useful in the diagnosis and monitoring of ovarian cancer. It also relates to an immunoassay method for detection of the antigen in serum for diagnosis and monitoring purposes.Type: GrantFiled: April 24, 1987Date of Patent: May 1, 1990Assignee: Research CorporationInventor: Timothy J. O'Brien
-
Patent number: RE33405Abstract: A prostate antigen distinct from prostatic acid phosphatase has been detected in normal, benign hypertrophic and malignant prostatic tissues, but not in other human tissues. The prostate antigen was purified to homogeneity from prostatic tissues by ammonium sulfate precipitation, DEAE-BioGel A anion exchange chromatography, molecular sievings on Sephadex G-100 and Sephadex G-75,This invention was supported in part by Grants No. CA-15126 and CA-15437 from the National Cancer Institute, U.S. Public Health Service.Type: GrantFiled: October 4, 1988Date of Patent: October 23, 1990Assignee: Research Corporation Technologies, Inc.Inventors: Tsann M. Chu, Ming C. Wang, Lawrence Papsidero